2021S0199-1 03/11/21
By: Johnson S.B. No. 1754
A BILL TO BE ENTITLED
AN ACT
relating to information provided by health care providers and
hospitals to certain patients regarding pharmaceutical
manufacturer patient assistance programs for insulin.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
SECTION 1. Subchapter J, Chapter 531, Government Code, is
amended by adding Section 531.354 to read as follows:
Sec. 531.354. INFORMATION ON PHARMACEUTICAL MANUFACTURER
PATIENT ASSISTANCE PROGRAMS FOR INSULIN. (a) This section applies
to health care providers and hospitals that receive uncompensated
care pool payments from the commission, including:
(1) Federally-qualified health centers as defined by
42 U.S.C. Section 1396d(l)(2)(B);
(2) rural health clinics as defined by 42 U.S.C.
Section 1396d(l)(1); and
(3) physician group practices.
(b) A health care provider or hospital to which this section
applies shall provide to patients who have diabetes and require
insulin information regarding the availability of pharmaceutical
manufacturer patient assistance programs, including copay cards,
that may reduce the cost of insulin to the patients.
(c) The executive commissioner shall adopt rules to
implement this section.
SECTION 2. If before implementing any provision of this Act
a state agency determines that a waiver or authorization from a
federal agency is necessary for implementation of that provision,
the agency affected by the provision shall request the waiver or
authorization and may delay implementing that provision until the
waiver or authorization is granted.
SECTION 3. This Act takes effect September 1, 2021.